Risperidone for prodromal phase of schizophrenia.

Reports on the positive clinical effects seen in adolescent patients with prodromal symptoms and a family history of schizophrenia, when they were subjected to an open label trial of low dose risperidone. Assessment of symptoms in both prodromal and first-episode patients after initial risperidone dosage; Effect of low dose and short-term treatment of risperidone on behavioral and neurocognitive functioning.